162 related articles for article (PubMed ID: 30185729)
1. [The role of pharmacology to produce firuglipel (DS-8500a), an orally available GPR119 agonist for type 2 diabetes mellitus].
Matsumoto K; Yoshitomi T; Shimada T
Nihon Yakurigaku Zasshi; 2018; 152(3):119-124. PubMed ID: 30185729
[TBL] [Abstract][Full Text] [Related]
2. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
[TBL] [Abstract][Full Text] [Related]
3. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study.
Yamada Y; Terauchi Y; Watada H; Nakatsuka Y; Shiosakai K; Washio T; Taguchi T
Adv Ther; 2018 Mar; 35(3):367-381. PubMed ID: 29488152
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive Evaluation of GPR119 Agonist Effects on β-Cell Mass in Diabetic Male Mice Using 111In-Exendin-4 SPECT/CT.
Murakami T; Fujimoto H; Fujita N; Hamamatsu K; Matsumoto K; Inagaki N
Endocrinology; 2019 Dec; 160(12):2959-2968. PubMed ID: 31613319
[TBL] [Abstract][Full Text] [Related]
6. GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present).
Li H; Fang Y; Guo S; Yang Z
Expert Opin Ther Pat; 2021 Sep; 31(9):795-808. PubMed ID: 33896337
[No Abstract] [Full Text] [Related]
7. The therapeutic potential of GPR119 agonists for type 2 diabetes.
Ohishi T; Yoshida S
Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
[TBL] [Abstract][Full Text] [Related]
8. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes.
Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M
Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753
[TBL] [Abstract][Full Text] [Related]
9. Discovery and characterization of novel small molecule agonists of G protein-coupled receptor 119.
Zhang SY; Li J; Xie X
Acta Pharmacol Sin; 2014 Apr; 35(4):540-8. PubMed ID: 24681896
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the G protein-coupled receptor 119 agonist DS-8500a in Japanese type 2 diabetes mellitus patients with inadequate glycemic control on sitagliptin: A phase 2 randomized placebo-controlled study.
Terauchi Y; Yamada Y; Watada H; Nakatsuka Y; Shiosakai K; Washio T; Taguchi T
J Diabetes Investig; 2018 Nov; 9(6):1333-1341. PubMed ID: 29607623
[TBL] [Abstract][Full Text] [Related]
11. Angelica dahurica Extracts Improve Glucose Tolerance through the Activation of GPR119.
Park EY; Kim EH; Kim CY; Kim MH; Choung JS; Oh YS; Moon HS; Jun HS
PLoS One; 2016; 11(7):e0158796. PubMed ID: 27391814
[TBL] [Abstract][Full Text] [Related]
12. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
Shah U; Kowalski TJ
Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion.
Yoshida S; Ohishi T; Matsui T; Shibasaki M
Biochem Biophys Res Commun; 2010 Sep; 400(3):437-41. PubMed ID: 20804735
[TBL] [Abstract][Full Text] [Related]
14. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
[TBL] [Abstract][Full Text] [Related]
15. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice.
Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
Biochem Biophys Res Commun; 2010 Nov; 402(2):280-5. PubMed ID: 20937249
[TBL] [Abstract][Full Text] [Related]
16. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.
Chu ZL; Jones RM; He H; Carroll C; Gutierrez V; Lucman A; Moloney M; Gao H; Mondala H; Bagnol D; Unett D; Liang Y; Demarest K; Semple G; Behan DP; Leonard J
Endocrinology; 2007 Jun; 148(6):2601-9. PubMed ID: 17289847
[TBL] [Abstract][Full Text] [Related]
17. GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates.
Hryciw DH; Patten RK; Rodgers RJ; Proietto J; Hutchinson DS; McAinch AJ
Expert Opin Investig Drugs; 2024 Mar; 33(3):183-190. PubMed ID: 38372052
[TBL] [Abstract][Full Text] [Related]
18. High-throughput screening for GPR119 modulators identifies a novel compound with anti-diabetic efficacy in db/db mice.
Zhang M; Feng Y; Wang J; Zhao J; Li T; He M; Yang D; Nosjean O; Boutin J; Renard P; Wang MW
PLoS One; 2013; 8(5):e63861. PubMed ID: 23704946
[TBL] [Abstract][Full Text] [Related]
19. A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression.
Kim MK; Cheong YH; Lee SH; Kim TH; Jung IH; Chae Y; Lee JH; Yang EK; Park H; Yang JS; Hong KW
Biomed Pharmacother; 2021 Dec; 144():112324. PubMed ID: 34678732
[TBL] [Abstract][Full Text] [Related]
20. GPR119 Agonism Increases Glucagon Secretion During Insulin-Induced Hypoglycemia.
Li NX; Brown S; Kowalski T; Wu M; Yang L; Dai G; Petrov A; Ding Y; Dlugos T; Wood HB; Wang L; Erion M; Sherwin R; Kelley DE
Diabetes; 2018 Jul; 67(7):1401-1413. PubMed ID: 29669745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
